Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo.


Journal

Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R

Informations de publication

Date de publication:
01 2019
Historique:
received: 22 06 2017
revised: 17 11 2017
accepted: 20 11 2017
pubmed: 9 12 2017
medline: 1 1 2019
entrez: 9 12 2017
Statut: ppublish

Résumé

Hepatitis delta virus (HDV) was shown to persist for weeks in the absence of HBV and for months after liver transplantation, demonstrating the ability of HDV to persevere in quiescent hepatocytes. The aim of the study was to evaluate the impact of cell proliferation on HDV persistence in vitro and in vivo. Genetically labelled human sodium taurocholate cotransporting polypeptide (hNTCP)-transduced human hepatoma(HepG2) cells were infected with HBV/HDV and passaged every 7 days for 100 days in the presence of the entry inhibitor Myrcludex-B. In vivo, cell proliferation was triggered by transplanting primary human hepatocytes (PHHs) isolated from HBV/HDV-infected humanised mice into naïve recipients. Virological parameters were measured by quantitative real time polymerase chain reaction (qRT-PCR). Hepatitis delta antigen (HDAg), hepatitis B core antigen (HBcAg) and cell proliferation were determined by immunofluorescence. Despite 15 in vitro cell passages and block of viral spreading by Myrcludex-B, clonal cell expansion permitted amplification of HDV infection. In vivo, expansion of PHHs isolated from HBV/HDV-infected humanised mice was confirmed 3 days, 2, 4 and 8 weeks after transplantation. While HBV markers rapidly dropped in proliferating PHHs, HDAg-positive hepatocytes were observed among dividing cells at all time points. Notably, HDAg-positive cells appeared in clusters, indicating that HDV was transmitted to daughter cells during liver regeneration even in the absence of de novo infection. This study demonstrates that HDV persists during liver regeneration by transmitting HDV RNA to dividing cells even in the absence of HBV coinfection. The strong persistence capacities of HDV may also explain why HDV clearance is difficult to achieve in HBV/HDV chronically infected patients.

Identifiants

pubmed: 29217749
pii: gutjnl-2017-314713
doi: 10.1136/gutjnl-2017-314713
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

150-157

Informations de copyright

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Katja Giersch (K)

I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Oliver D Bhadra (OD)

I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Tassilo Volz (T)

I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Lena Allweiss (L)

I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Kristoffer Riecken (K)

Department of Stem Cell transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Boris Fehse (B)

Department of Stem Cell transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Ansgar W Lohse (AW)

I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel and Heidelberg Partner sites, Germany.

Joerg Petersen (J)

IFI Institute for Interdisciplinary Medicine, Asklepios Clinic St. Georg, Hamburg, Germany.

Camille Sureau (C)

Laboratoirede Virologie Moleculaire, INTS, Centre National de la Recherche Scientifique, Paris, France.

Stephan Urban (S)

German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel and Heidelberg Partner sites, Germany.
Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.

Maura Dandri (M)

I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel and Heidelberg Partner sites, Germany.

Marc Lütgehetmann (M)

Institute of Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH